Diagnosis and management of non-criteria obstetric antiphospholipid syndrome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Summary: Accurate diagnosis of obstetric antiphospholipid syndrome (APS) is a prerequisite for optimal clinical management. The international consensus (revised Sapporo) criteria for obstetric APS do not include low positive anticardiolipin (aCL) and anti β2 glycoprotein I (aβ2GPI) antibodies (> 99th centile) and/or certain clinical criteria such as two unexplained miscarriages, three non-consecutive miscarriages, late preeclampsia, placental abruption, late premature birth, or two or more unexplained in vitro fertilisation failures. In this review we examine the available evidence to address the question of whether patients who exhibit non-criteria clinical and/or laboratory manifestations should be included within the spectrum of obstetric APS. Prospective and retrospective cohort studies of women with pregnancy morbidity, particularly recurrent pregnancy loss, suggest that elimination of aCL and/or IgM aβ2GPI, or low positive positive aCL or aβ2GPI from APS laboratory diagnostic criteria may result in missing the diagnosis in a sizeable number of women who could be regarded to have obstetric APS. Such prospective and retrospective studies also suggest that women with non-criteria obstetric APS may benefit from standard treatment for obstetric APS with low-molecular-weight heparin plus low-dose aspirin, with good pregnancy outcomes. Thus, non-criteria manifestations of obstetric APS may be clinically relevant, and merit investigation of therapeutic approaches. Women with obstetric APS appear to be at a higher risk than other women of pre-eclampsia, placenta- mediated complications and neonatal mortality, and also at increased long-term risk of thrombotic events. The applicability of these observations to outcomes in women with non-criteria obstetric APS remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Middeldorp, S., Veenstra, D. L., Prabulos, A.-M., & Vandvik, P. O. (2012) · Chest · doi:10.1378/chest.11-2300 · Cited by 1,525 · cited 5×
“The ACCP guidelines also recommend that these women with obstetric APS should be treated with prophylactic or intermediate dose unfractionated heparin (UFH) or prophylactic dose LMWH combined with LDA (75 to 100 mg/ daily), in the antepartum period as soon as pregnancy is confirmed.”
BackgroundInfluentialRai, R., & Regan, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69204-0 · Cited by 1,227
Rai, R., Cohen, H., Dave, M., & Regan, L. (1997) · BMJ · doi:10.1136/bmj.314.7076.253 · Cited by 1,113
Self-citationCervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972 · cited 1×
“A meta-analysis of the association between aPL and recurrent fetal loss in women without autoimmune disease, reported that LA, which appears to have the strongest association with thrombosis (23), was associated with late recurrent pregnancy loss (odds ratio [OR] 7.”
BackgroundRecurrent miscarriage I: definition and epidemiology
Stirrat, G. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)92159-f · Cited by 600
LASKIN, C. A., SPITZER, K. A., CLARK, C. A., CROWTHER, M. R., GINSBERG, J. S., HAWKER, G. A., KINGDOM, J. C., BARRETT, J., & GENT, M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080763 · Cited by 352
Cervera, R., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Kiss, E., Zeher, M. M., Tincani, A., Kontopoulou-Griva, I., Galeazzi, M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093179 · Cited by 286
Rai, R. S., Regan, L., Clifford, K., Pickering, W., Dave, M., Mackie, I., McNally, T., & Cohen, H. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136224 · Cited by 238
Self-citationAntibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity
Ruffatti, A., Tonello, M., Del Ross, T., Cavazzana, A., Grava, C., Noventa, F., Tona, F., Iliceto, S., & Pengo, V. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-05-0287 · Cited by 170 · cited 1×
“Although triple positivity (the co-existence of LA, aCL and aβ2 GPI) is associated with a significantly higher rate of pregnancy loss in obstetric APS (46), a single positive aPL test, more often aCL or aβ2GPI alone rather than LA, has been reported to be more common in purely obstetric APS (10, 19).”
BackgroundRUFFATTI, A., OLIVIERI, S., TONELLO, M., BORTOLATI, M., BISON, E., SALVAN, E., FACCHINETTI, M., & PENGO, V. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03121.x · Cited by 134 · cited 1×
“(47) reported that the rate of aCL values between the 99th centile (17.”
BackgroundDiagnosis of antiphospholipid syndrome in routine clinical practice
Gardiner, C., Hills, J., Machin, S., & Cohen, H. (2013) · Lupus · doi:10.1177/0961203312460722 · Cited by 131 · cited 8×
“Evidence is accumulating on the potential clinical significance of these non-criteria clinical and laboratory manifestations of obstetric APS (8, 10, 13, 14) (▶ Table 1B).”
BackgroundInfluentialRecurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy
COHN, D. M., GODDIJN, M., MIDDELDORP, S., KOREVAAR, J. C., DAWOOD, F., & FARQUHARSON, R. G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04015.x · Cited by 99 · cited 5×
“Evidence is accumulating on the potential clinical significance of these non-criteria clinical and laboratory manifestations of obstetric APS (8, 10, 13, 14) (▶ Table 1B).”
BackgroundResultInfluentialMarked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome
Topping, J. (1999) · Human Reproduction · doi:10.1093/humrep/14.1.224 · Cited by 57
van den Boogaard, E., Cohn, D. M., Korevaar, J. C., Dawood, F., Vissenberg, R., Middeldorp, S., Goddijn, M., & Farquharson, R. G. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.09.002 · Cited by 36
Cited by
Bashiri, A., Halper, K. I., & Orvieto, R. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0414-2 · Cited by 598
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH
Devreese, K. M. J., Ortel, T. L., Pengo, V., & de Laat, B. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13976 · Cited by 269
Toth, B., Würfel, W., Bohlmann, M., Zschocke, J., Rudnik-Schöneborn, S., Nawroth, F., Schleußner, E., Rogenhofer, N., Wischmann, T., von Wolff, M., et al. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0586-4568 · Cited by 119
“Based on current studies, non-criteria aPL syndrome should be treated in exactly the same way, as a few studies have indicated a potential benefit from the administration of LMWH in combination with ASA [126 – 130].”
Immunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art
Vomstein, K., Feil, K., Strobel, L., Aulitzky, A., Hofer-Tollinger, S., Kuon, R.-J., & Toth, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040869 · Cited by 113
Metadata
- Authors
- Machin, S. J., Mackie, I. J., Cohen, H., & Jayakody Arachchillage, D. R.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015-01
- Volume
- 113
- Issue
- 01
- Pages
- 13-19
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2137221463
- Cited by
- 97
- References
- 16
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.